. 2020 Dec 5;59(Suppl 5):v19–v28. doi: 10.1093/rheumatology/keaa420

Table 1.

Definition of LLDAS, DORIS clinical remission on treatment and DORIS complete remission

LLDAS	DORIS clinical remission on treatment^a	DORIS complete remission^b
SLEDAI-2K ≤4, with no activity in major organ systems and no new features of activity compared to previous assessment	Clinical SLEDAI=0	Clinical SLEDAI=0
Serological activity allowed (as long as total SLEDAI-2K ≤4)	Serological activity allowed	No serological activity
SELENA-SLEDAI PGA ≤1 (scale 0–3)	SELENA-SLEDAI PGA ≤0.5 (scale 0–3)	SELENA-SLEDAI PGA ≤0.5 (scale 0–3)
Current prednisolone (or equivalent) dose ≤7.5 mg	Low-dose glucocorticoids (e.g. prednisone ≤5 mg/ day) allowed	No glucocorticoids
Standard maintenance doses of immunosuppressive drugs and approved biological agents, excluding investigational drugs	Maintenance antimalarials, immunosuppressives and/or stable (maintenance) biologics allowed	Maintenance antimalarials allowed, but no immunosuppresives and/or biologics

Serological activity – elevation of antibodies to dsDNA levels above the upper limit of laboratory normal or lowering of complement component 3 and/or 4 levels below the lower limit of laboratory normal. ^aMost attainable of the eight possible definitions of remission. ^bLeast attainable of the eight possible definitions of remission. DORIS: definitions of remission in systemic lupus erythematosus; LLDAS: lupus low disease activity state; PGA: physician global assessment; SELENA-SLEDAI: Safety of Estrogen in Lupus National Assessment-SLEDAI; SLEDAI-2K: SLEDAI 2000.